Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership

Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab...

      

Related Stories

• Exonate Sees Alternative mRNA Splicing Inhibitors As New Eye Disease Therapies
• Pfizer May Enjoy Blockbuster Cardiomyopathy Success With Tafamidis
• Call For India Compulsory Licenses For Last Resort TB Drugs

 

Original Article: Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership

More From BioPortfolio on "Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership"